Vaccinal Preventon of Anthrax in the Russian Federation and Its Immediate Prospects

The purpose of the work is to show the possibilities of vaccine prophylaxis of anthrax in the Russian Federation and its immediate prospects. The article is dedicated to the vaccine preparations, available in Russia and abroad in the arsenal of medical remedies at present, to the history of their creation, to the effectiveness of their use and to the main directions of the improving of the vaccine prevention. The efforts to develop a new generation of vaccines are aimed mainly at the increasing of the safety of vaccines, reducing the frequency of their administration and improving their production technologies. The combined anthrax vaccine developed in the USSR can be used in the emergency prophylaxis of anthrax along with antibiotics. The development of vaccines based on immunogenic antigens synthesized by recombinant producers solves the problem of residual virulence and reactogenicity, as well as the problem of increasing stability and reduction of doses of modern anthrax vaccines. In the nearest future it is necessary: to develop an industrial technology of the production of anthrax vaccines based on recombinant strains – hyperproducers of protective antigen and include them in the prophylaxis and treatment regimens of anthrax infection; to develop scientific and methodological approaches and vaccines for mass immunization against anthrax; to evaluate the possibility of using new adjuvants for the construction of anthrax vaccines, more effective and safer than the existing ones.

1. Pavlov D.L., Onuchina N.V., Kuznetsovskiy A.V. et al. Results of study of the biological properties of anthrax isolates of the 2016 epizootic episode in the Yamalo-Nenets Autonomous District // Journal of NBC protection corps. 2017. V. 1. № 1. P. 23–32 (in Russian).

2. Mikshis N.I., Popova P.Yu., Semakova A.P., Kutyrev V.V. Licensed Anthrax Vaccines and Experimental Preparations at the Stage of Clinical Trials // Journal of Microbiology, epidemiology, immunobiology. 2017. № 4. P. 112–126 (in Russian).

3. Cherkassky B.L. Epidemiology and prevention of anthrax. M.: «INTERSEN», 2002. 382 p (in Russian).

4. Anthrax: асtuаl problems of elaboration and introduction in practice of medical defense means // Eds. Onishchenko G.G., Darmov V.V., Borisevich S.V. Sergiev Posad. 2018. 591 p. (in Russian).

5. Onishchenko G.G., Vasilyev N.T., Litusov N.V. Anthrax: actual aspects of microbiology, epidemiology, clinical picture, diagnosis, treatment and prevention. M.: VUNMTS Ministry of Health of Russian Federation, 1999. 448 p (in Russian).

6. Saltykov R.A. Vaccinal prophylaxis of anthrax in humans // Problems of especially dangerous infections. 1971. V. 1(17). P. 173–176 (in Russian).

7. Artenstein A.W. Vaccines: a biography. New York. London. 2010.

8. Burgasov P.N., Rozhkov G.I. Anthrax. Moscow; 1984 (in Russian).

9. Patent RF № 2115433 (1998) (in Russian).

10. Sadovoy N.V., Sadovaya E.A., Sayapina L.V., et al. Designing and studying the immunogenic properties of a combined anthrax vaccine // Actual problems of biological protection of troops and the population. Diagnosis, treatment and prevention of dangerous infectious diseases. Epidemiology and epizootology. Microbiology. Biotechnology. Ecology: mater. All-Russia. Scientific practical conf. dedicated The 60th anniversary of the branch of the FSI «48 Central Research Institute of the Ministry of Defense of Russia TsVTP BZ». Yekaterinburg. 2009. P. 121–122 (in Russian).

11. Seroglazov V.V., Kozhukhov V.V., Kravets I.D., et al. Comparative evaluation of the effectiveness of the combined anthrax vaccine in laboratory and farm animals // Immunology and specific prevention of the PED. mater. Russian scientific conf. (September 21-23, 1993). Saratov. 1993. P. 195 (in Russian).

12. Bailie L. Anthrax vaccine development work at CBD Porton Down // 4th International Conference on Anthrax, 10-13 June, 2001, Anapolis, Maryland, USA, 2001.

13. Bailie L. Flick-Smith H.C., Eyles J.E. et al. Immunization with microencapsulated PA // 4th International Conference on Anthrax, 10-13 June, 2001, Anapolis, Maryland, USA, 2001.

14. Willamson E.D., Hodgson I., Walker N.J. et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax // Infect. Immun. 2005. V. 73, № 9. Р. 5978–5987.

15. Patent RF № 263502 (1987) (in Russian).

16. Buravtseva N.P., Kogotkova O.P., Tsygankova O.I. et al. Comissioning testing of anthrax vaccines in humans // Diagnostics, treatment and prevention of the dangerous and especially dangerous infectious diseases. Biotechnology: mater. All-Russia scientific practical conf. dedicated The 80th anniversary of the founding of the branch of the FSI «48 Central Research Institute of the Ministry of Defense of Russia». Kirov. 2008. P. 53–58 (in Russian).

17. Buravtseva N.P., Eremenko E.L., Aksenova L. Yu. Prospects for the use of anthrax vaccine STI-PR // Actual problems of epidemiology safety: mat. anniversary scientific practical conf. dedicated The 50th anniversary of the Stavropol Research Anti-Plague Institute (October 1516, 2002). Stavropol. 2002. P. 52–53 (in Russian).

18. Jackson P.J., Hill K.K., Laker M.T, Tickn L.O. Comparison of B.anthracis an fragment length polymorphism and polymerase chain in PCR // J. Appl. Microbiol. 1997. V. 87. P. 263–269.

19. Kenney R.T., Yu J., Guebre-Xabier M. et al. Induction of Protective Immunity against Lethal Anthrax Challenge with a Patch // J. Infect. Dis. 2004. V. 190. P. 774–782.

20. Kokushkin A.M., Velichko L.N., Knyazeva T.V. et al. Studying the role of one´s own plasmids and the sign of pigment sorption in the ability of plague bacteria to infect fleas and cause block formation in them // Natural focal infections and their prevention. Saratov. 1991. P. 110–118 (in Russian).

21. Supotnitsky M.V. Biological war. Introduction to the epidemiology of artificial epidemic process. M.: «The Department», Russian Panorama», 2013. 1136 p. (in Russian).

22. Xic H., Gursel I., Ivins B.E et al. GPG Oligodeoxynucleotides absorbed on to polylactidecoglycolide microparticles improve the licensed anthrax vaccine// Infect and Immun. 2003. V. 73. № 2. Р. 828–833.

23. Riviere G., Choumet V., Salion S. et al. Absorption and elimination of viper venoms after antivenom administration // Pharmacol, exp. Ther. 1998. V. 285. Р. 490–495.

24. Jordan Report 20th Anniversary. Accelerated Development of Vaccines. Ed. Hilleman J. Washington, 2002.

25. Vorobyev A.A., Semenov B.F., Egorova N.B. The expected prospects of vaccinology until 2020 // Fundamential directions of molecular medicine. Spb., 2005. P. 328–392 (in Russian).

26. Semenov B.F., Zverev V.V., Khaitov R.M. Vaccine prophylaxis in the 21st century: present and future // Immunology. №6. 2009. P. 324–335 (in Russian).

27. Kogotkova O.P., Aksenova L.Yu., Buravtseva N.P. et al. Combined use in the experiment anthrax vaccine STIPR with licopidum. Medical Microbiokogy – XXI century // mat. All-Russia. scientific practical. conf. (September 2830, 2004). Saratov. 2004. P. 119–120 (in Russian).

28. Kogotkova O.P., Buravtseva N.P. Improving the effectiveness of non-specific and specific protection for anthrax infection with immunomodulators // Mat. anniversary scientific practical conf. dedicated The 100th anniversary of the formation Anti-Plague Service of Russia (September 16-18, 1997). Saratov. 1997. V. 1. P. 220 (in Russian).

29. Pimenov E.V., Darmov I.V., Vasilyev I.T. et al. The state of the issue and prospects for the development of vaccines against anthrax // Epidemiology and vaccination. 2002. № 5. P. 42–46 (in Russian).

30. US Patent № 441711 (1974).

31. Alinger B.A., Roehrl M.H., Mekalonos J.J et al. Combining anthrax vaccine and terapy a dominantNegative Inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines // Infect. Immun. 2005. V. 73. № 6. Р. 3408–3414.

32. Bever W. Vaccination strategies for anthrax prevention // Ber. Münch. Tierärtl. Wschr. 2004. V. 11. № 2. Р. 237–244.

33. Scobie H.M., Wigelsworth D.J., Marlett J.M et al. Anthrax toxin receptor 2-de-terminants of Lethal toxin killing in vivo // PloS Pathogens. 2006. V. 2. Issue 10. e111. http://www.plospatho-gens.org.

34. Kasuva K., Bover J.L. Passive immunization for anthrax toxin mediated by an adenovirus expressing an antiprotective antigen single chain antibody // Molec. Ther. 2005. V. 11. № 2. Р. 237–244.

35. Miksata J.A., Sullivan V.J., Dean C. et al. Protective immunization against inhalation anthrax: a comparison of minimally invasive delivery platforms // J. Infect. Dis. 2005. V. 191. Р. 278–288.

36. Vorobyev A.A. Physiological routes of administration of antigens and other biologically active substances into the body // Immunology. 1996. № 5. P. 4–8 (in Russian).

37. Loktev N.A. On the mechanisms of formation of resistance to plague, tularemia and anthrax with associated needleless vaccination. Actual issues of prevention of dangerous infectious diseases. Kirov. 1991. P. 144–145 (in Russian).

38. Vorobyev A.A., Lebedinsky V.A. Mass ways of immunization. M.: «Medicine». 1977. 256 p. (in Russian).